New drug cocktail shows promise for Tough-to-Treat stomach cancer

NCT ID NCT06932068

Recruiting now Disease control Sponsor: Qilu Hospital of Shandong University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) plus standard chemotherapy can help people with advanced HER2-negative stomach cancer that has low PD-L1 levels. The study will enroll 77 participants and measure how long the cancer stays under control, overall survival, and tumor shrinkage. It is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and tuvonralimab (QL1706) combined with chemotherapy (oxaliplatin and capecitabine)
What this could lead to: If successful, this could offer a new treatment option for people with advanced gastric cancer who have limited immunotherapy choices.
What could go wrong: This is a small, early-phase trial with no comparison group, so results may not be definitive. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE LOW PD-L1 EXPRESSING UNRESECTABLE OR METASTATIC GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Affiliated Hospital of Jining Medical College
RECRUITING

Jining, Shandong, China
Binzhou Medical University Hospital
RECRUITING

Binzhou, Shandong, China
Dezhou People's Hospital
RECRUITING

Dezhou, Shandong, China
Jinan Central Hospital
RECRUITING

Jinan, Shandong, China
Jinan Third People's Hospital
RECRUITING

Jinan, Shandong, China
Jining First People's Hospital
RECRUITING

Jining, China
Liaocheng People's Hospital
RECRUITING

Liaocheng, Shandong, China
Linyi Cancer Hospital
RECRUITING

Linyi, Shandong, China
Linyi People's Hospital
RECRUITING

Linyi, Shandong, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250012, China
Qilu Hospital of Shandong University(Qingdao)
RECRUITING

Qingdao, Shandong, 250063, China
Qingdao Municipal Hospital
RECRUITING

Qingdao, Shandong, China
Qingdao Municipal Hospital
RECRUITING

Qingdao, Shandong, China
Shandong Provincial Hospital Affiliated to Shandong First Medical University
RECRUITING

Jinan, Shandong, 250012, China
Shandong Provincial Third Hospital
RECRUITING

Jinan, Shandong, 250012, China
Shandong Qianfoshan Hospital
RECRUITING

Jinan, Shandong, China
Shengli Oilfield Central Hospital
RECRUITING

Dongying, Shandong, China
Taian City Central Hospital
RECRUITING

Tai’an, Shandong, China
Tengzhou Central People's Hospital
RECRUITING

Tengzhou, Shandong, 277599, China
The Affiliated Hospital of Qingdao University
RECRUITING

Qingdao, Shandong, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450052, China
The Second Affiliated Hospital of Shandong First Medical University
RECRUITING

Tai’an, Shandong, China
Weifang Hospital of Traditional Chinese Medicine
RECRUITING

Weifang, Shandong, China
Weihai Central Hospital
RECRUITING

Weihai, Shandong, China
Yantai Yuhuangding Hospital
RECRUITING

Yantai, Shandong, China
Yantai Yuhuangding Hospital
RECRUITING

Yantai, Shandong, China
Yantaishan Hospital
RECRUITING

Yantai, Shandong, China
Zibo Central Hospital
RECRUITING

Zibo, Shandong, China
Zibo First People's Hospital
RECRUITING

Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.